Claude Nicaise - 29 Jan 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise
Issuer symbol
SRPT
Transactions as of
29 Jan 2026
Net transactions value
+$15.6
Form type
4
Filing time
29 Jan 2026, 20:05:03 UTC
Previous filing
25 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nicaise Claude Director 215 FIRST STREET, SUITE 415, CAMBRIDGE /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise 29 Jan 2026 0001644162

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Options Exercise $143,955 +10,500 +38% $13.71 38,312 29 Jan 2026 Direct
transaction SRPT Common Stock Tax liability $143,939 -6,780 -18% $21.23 31,532 29 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRPT Stock Option (right to buy) Options Exercise $0 -10,500 -100% $0.000000 0 29 Jan 2026 Common Stock 10,500 $13.71 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not wittheld by the Issuer.